In biotech, when you hear that a drug's peak sales estimates hover around $200 million, usually you shrug. But for a stock like Amicus Therapeutics (NASDAQ:FOLD), with a market cap of under $300 million, suddenly $200 million in potential sales looks like a big deal.
Amicus announced yesterday that it would be reporting data from its phase 3 study (titled "Study 012") for Migalast HCL for Fabry Disease sometime in third quarter. And today shareholders got even better news, as analysts moved their price targets on the stock, reflecting increasing market optimism that this drug will perform well.
But is the stock a good investment? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their two cents on Amicus.
Leaked: This coming blockbuster will make even Amicus jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.